Sterile Cleanroom Wipes - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Sterile Cleanroom Wipes


VAI’s Sterile Cleanroom Wipes use innovative manufacturing technologies, and the single source dedicated supply chain allow for the vertical manufacturing process to be completely traceable from start to finish.

VAI’s wipes are knitted with continuous monofilament polyester and are cut using a “focused edge” cutting technology. This eliminates the risk of particulates being introduced into classified areas, by improving the edge over traditional laser cutting.

All wipes are quality assurance tested and released to specifications defined by IEST and ASTM methods.

VAI’s wipes are made with one material (dry or saturated) for easy inexpensive validation and consistency throughout your manufacturing areas.  All versions of dry or saturated wipes are manufactured under cGMP’s, are lot traceable and validated.

VAI’s high quality wipes are available in WipeDown® dry wipes, Procees2Wipe® (USP IPA and WFI Quality Water), HYPO-CHLOR® WFI formula in 0.25%, 0.52%, and 5.25%, STERI-PEROX® WFI formula 3% and 6%, DECON-Clean® RTU residue remover, individually packaged Alcoh Wipes®, STEEL-BRIGHT® Wipes and DAS® Wipes.

VAI

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here